HUMACYTE INC. - COMMON STOCK

Humacyte Announces Presentation of First Eight Expanded Access Cases Using Human Acellular Vessel™ (HAV) for Treatment of Critical Limb Ischemia at 46th Annual Winter Meeting of the Vascular and Endovascular Surgery Society

06 Jan 2022 07:30:00 By Nasdaq GlobeNewswire

Humacyte Announces Presentation of First Preclinical Results of the HAV™ in Coronary Artery Bypass Grafting at Advanced Therapies Week Conference

04 Jan 2022 07:30:00 By Nasdaq GlobeNewswire

Humacyte Announces the Appointments of Three Surgical and Cardiovascular Opinion Leaders to Advisory Roles

31 Dec 2021 07:30:00 By Nasdaq GlobeNewswire

Humacyte Announces Publication Highlighting the First Use of the Human Acellular Vessel (HAV™) as Arterial Bypass Conduit for Replacement of Infected Prosthetic Graft

15 Dec 2021 07:30:00 By Nasdaq GlobeNewswire

Humacyte Presents Preclinical Results of Small-Diameter HAV™ for Use as a BTT Shunt in Pediatric Heart Disease at American Heart Association’s Scientific Sessions 2021

16 Nov 2021 07:30:00 By Nasdaq GlobeNewswire

Humacyte Presents New 12-Month Data from HAVs™ Produced Using Commercial-Scale Manufacturing System

15 Nov 2021 09:30:00 By Nasdaq GlobeNewswire

Humacyte Reports Third Quarter 2021 Financial Results and Provides Business Highlights

12 Nov 2021 07:30:00 By Nasdaq GlobeNewswire

Humacyte Leadership to Present at Credit Suisse 30th Annual Healthcare Conference

09 Nov 2021 07:30:00 By Nasdaq GlobeNewswire

Humacyte Leadership to Present at Multiple Scientific Events in November

08 Nov 2021 07:30:00 By Nasdaq GlobeNewswire

Humacyte Leadership to Present at Seven Scientific and Industry Events in October

05 Oct 2021 07:30:00 By Nasdaq GlobeNewswire

Humacyte Announces Issuance of Three Additional U.S. Patents Covering its Proprietary Universally Implantable Bioengineered Human Tissue Platform

20 Sep 2021 08:45:00 By Nasdaq GlobeNewswire

Humacyte Leadership to Present at Five Scientific Events in September

17 Sep 2021 07:51:42 By Nasdaq GlobeNewswire